Search for: "Novartis Ag"
Results 321 - 340
of 440
Sorted by Relevance
|
Sort by Date
27 Jul 2010, 8:20 am
” My “in group” is the group of people who are like me in salient ways such as gender, race, religion, age, educational background, profession, family status, etc. [read post]
17 Nov 2010, 1:48 am
(Patent Baristas) A round up of international events – Access and Benefit Sharing Protocol; review of Para 6 system; concerns with ACTA’s compatibility with TRIPS(Spicy IP) Compromise UN protocol treaty against biopiracy adopted in Japan (IP Watch) (Innovation Law Blog) TRIPS Council discusses efficacy of ACTA, public health amendment (IP Watch) Altering genes in crops (IP Osgoode) Asia Pacific Pharmas moving away from generics (GenericsWeb) Belgium Commercial Court: No faultless… [read post]
3 Aug 2020, 7:02 am
Where there are specialists with a focus on the kind of work with which a patent is concerned, they are the relevant addressees of the patent and their specialist skills are attributed to the notional skilled person, even if the patent might also be of a broader application and of interest to non-specialists (Medimmune Ltd v Novartis Pharmaceuticals UK Ltd [2013] RPC 27). [read post]
28 Apr 2019, 8:20 am
In the Rituximab case (District Court of Munich, May 2017), the court said that the generic case law stipulating that the balance of interests in principle favors the originator cannot be applied to biosimilar situations and that a full assessment of the specific circumstances is required in each case.From the audience Jürgen Dressel (ex-Novartis Pharma AG, Basel) asked about the uptake of biosimilars and whether costs will decrease the more medicines healthcare systems… [read post]
22 Sep 2016, 5:32 pm
An ageing population and the increase in chronic diseases are driving a dramatic market expansion. [read post]
14 Jun 2022, 1:15 pm
” Alcon alleged that Lens.com infringed its trademark rights (including rights inherited from Novartis AG) by doing so. [read post]
8 Jan 2021, 3:49 am
.'" Novartis AG v. [read post]
30 Apr 2019, 5:29 am
Jürgen Dressel (ex- Novartis Pharma AG) further commented that of course there is the further issue in Germany that invalidity proceedings cannot even be commenced whilst EPO opposition proceeding are ongoing. [read post]
26 Jun 2013, 6:43 am
It is therefore insufficient: see Novartis AG v Johnson & Johnson Medical Ltd [2010] EWCA Civ 1039, [2011] ECC 10 at [77]. [read post]
7 May 2013, 8:53 am
This was explained by Kitchin J in Novartis AG v Johnson & Johnson Medical Ltd [2009] EWHC 1671 (Pat) at [122] as follows, having cited a passage from G2/98: “I discern from this passage that the EPO considers it is permissible to afford different priority dates to different parts of a patent claim where those parts represent a limited number of clearly defined alternative subject-matters and those alternative subject-matters have been disclosed (and are enabled) by… [read post]
3 Mar 2015, 1:55 am
Counsel for Pfizer drew analogy between this situation and “the situation where an injunction is sought pending appeal even though the patent has been held invalid at first instance, as to which see Novartis AG v Hospira UK Ltd [2013] EWCA Civ 583, [2014] 1 WLR 1264. [read post]
4 Sep 2023, 1:05 am
(Dec 2021)SPCs based on a second marketing authorisation - the fight continues (Novartis C-354/19) (Jun 2019)Article 3(a) just keeps on giving: AG Opinion in SPC referrals C-650/17 and C-114/18 (Sep 2019)Does the Irish Court of Appeal in Merck v Clonmel part ways from the CJEU's Santen Article 3(d) decision? [read post]
18 May 2015, 11:01 am
| OHIM’s rebranding | LV’s pattern as trade mark | EPO and trade unions | Patent and first-mover advantage | Libraries’ right to digitise their collection in Germany.Never too late 42 [week ending on Sunday 19 April] – WIPO Roving Seminars in Israel | Foster v Svenson, or "of taking pictures of your neighbours" | Trade marks and social networks | Jan Rosen on CJEU's public criterion to assess whether linking amounts communication to the… [read post]
6 Apr 2019, 9:46 am
AG Szpunar thinks not necessarily | The CNY 260 million fine on QVOD is final! [read post]
5 Sep 2014, 12:31 am
A serogroup B vaccine (Bexsero, Novartis) was licensed in Europe, Australia, and Canada in 2013 and has received a "breakthrough therapy" designation from the Food and Drug Administration.Employers should be familiar with laboratory biosafety recommendations and ensure that a laboratory biosafety program is in place. [read post]
27 Mar 2019, 11:33 am
AG Szpunar thinks not necessarily | The CNY 260 million fine on QVOD is final! [read post]
2 Mar 2015, 2:43 pm
| Dutch diverge with English as Novartis prevails on Zoledronic Acid in Netherlands | Slogan and TMs | The coffee capsule wars | Declining public trust in innovation | IPEC’s ruling in Global Flood Defence Systems& Another v Van den Noort Innovations BV & Others | Again on CJEU ruling in Case C-419/13 Art & Allposters | Biotech financing: the risk components, ‘going long’ and patents as knowledge currency. [read post]
24 Mar 2019, 3:26 pm
AG Szpunar thinks not necessarily | The CNY 260 million fine on QVOD is final! [read post]
27 Nov 2023, 8:00 pm
In Novartis AG v. [read post]
19 Apr 2011, 5:04 pm
Infosint (IPKat) (PatLit) Clobex (Clobetasol) – US: Galderma, Dermalogix agree to end Clobex suit with Paddock (Patent Docs) Crestor (Rosuvastatin) – US: Palmetto files patent infringement suit against AstraZeneca based on its Crestor product; AstraZeneca files for declaratory judgment of non-infringement and invalidity (Patent Docs) Drospirenone, Ethinylestradiol – UK: Shedding further light on obviousness: Gedeon Richter PC v Bayer Schering Pharma AG (Kluwer Patent Blog)… [read post]
